^
    23h
    DarbeLus: Luspatercept + Darbepoetin in MDS (clinicaltrials.gov)
    P2, N=60, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Reblozyl (luspatercept-aamt) • Aranesp (darbepoetin alfa)
    1d
    SURPASS-IPF: Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov)
    P3, N=1100, Not yet recruiting, PureTech
    New P3 trial • Head-to-Head
    2d
    Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 (clinicaltrials.gov)
    P1, N=66, Recruiting, Shanghai Pushi Medical Science Co. Ltd | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial primary completion date
    3d
    Unravelling the Crosstalk: Anti-Fibrotic Agents and MAPK Inhibitors in the Treatment of Melanoma. (PubMed, Crit Rev Oncol Hematol)
    Targeting fibrotic pathways such as TGF-β, FGF, and PDGF signalling, with medications like nintedanib and pirfenidone, may help overcome the resistance mechanisms associated with MAPK inhibitor therapy. This review unravels the complex interactions between MAPK inhibitors and anti-fibrotic drugs in the treatment of melanoma, highlighting how they might work together to remodel the TME and overcome treatment resistance. Implementing this combinatorial method could lead to novel approaches for long-term melanoma control and provide a model for anti-fibrotic-based treatments for other solid cancers.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    nintedanib
    3d
    A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027) (clinicaltrials.gov)
    P1, N=146, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Winrevair (sotatercept-csrk)
    7d
    L-arginine-induced chronic pancreatitis in mice: Evaluating effects of pirfenidone and simvastatin. (PubMed, World J Gastrointest Pharmacol Ther)
    Combination of pirfenidone and simvastatin demonstrated a synergistic therapeutic effect in reducing inflammation, fibrosis, and oxidative stress in an L-arginine-induced chronic pancreatitis mouse model, suggesting promise for chronic pancreatitis management.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    simvastatin
    8d
    Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms (clinicaltrials.gov)
    P2, N=70, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Suspended --> Recruiting
    Enrollment open
    |
    SF3B1 (Splicing Factor 3b Subunit 1)
    |
    SF3B1 mutation
    |
    Reblozyl (luspatercept-aamt)
    13d
    Antiproliferative Therapies in Pulmonary Arterial Hypertension. (PubMed, Expert Opin Pharmacother)
    Targeting these pathways, including BMPR2 restoration, TGF-β inhibition, and tyrosine kinase blockade, has shown encouraging results beyond the vasodilator-focused standard of care. These innovations may reshape PAH management by improving outcomes, and potentially altering disease progression.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Winrevair (sotatercept-csrk)
    13d
    SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Philipps University Marburg
    New P2 trial
    |
    Winrevair (sotatercept-csrk)
    13d
    SOTERIA: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (clinicaltrials.gov)
    P3, N=815, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Winrevair (sotatercept-csrk)
    13d
    A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) (clinicaltrials.gov)
    P2, N=130, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial completion date: Sep 2027 --> Jun 2028 | Trial primary completion date: Sep 2027 --> Jun 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Winrevair (sotatercept-csrk)
    13d
    LIGHTRAY: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) (clinicaltrials.gov)
    P2, N=164, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Winrevair (sotatercept-csrk)